Patent · US Active

Insulin delivery safety

US9597451B2 · kind B2 · utility

4Cited by

1References

20Claims

0Family size

Assignee

Roche Diagnostics Operations, Inc. · US

Inventors

Ofer Yodfat · Lod, IL
Gali Shapira · Haifa, IL
Iddo Gescheit · Nes Ziona, IL

Key dates

Filing date	Feb 11, 2010
Grant date	Mar 21, 2017
Priority date	—
Expiry date	Jun 29, 2033

Classification

Technology area (CPC G)Physics
CPC primaryG16H50/50
WIPO fieldMedical technology
WIPO sectorInstruments

Abstract

Embodiments of the present disclosure are directed to systems, devices/apparatuses and methods for assessing a residual insulin value for a user/patient. Such embodiments may be implemented by selecting a first value corresponding to a duration of insulin action; selecting a second value corresponding to a lock out time duration, selecting a first time period beginning at a time point T0 minus the first value and ending at the time point T0 minus the second value, selecting one or more boluses delivered during the first time period; for each of the one or more boluses selecting a corresponding residual insulin value estimated at the time point T0, computing the cumulative residual insulin value by summation of the corresponding residual insulin values.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.